arrow
E

Edwin M. Spithoven

Amphia Hospital
H指数:14
被引数:928

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease
2019-08-0140
OAAI
Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease The DIPAK 1 Randomized Clinical Trial

兰瑞肽对常染色体显性多囊肾病患者肾功能的影响DIPAK 1随机临床试验

2018-11-2075
OAAI
The Association of Combined Total Kidney and Liver Volume with Pain and Gastrointestinal Symptoms in Patients with Later Stage Autosomal Dominant Polycystic Kidney Disease
2017-09-0817
OAAI
Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study

在常染色体显性多囊肾疾病中使用生长抑素类似物兰瑞肽期间的肝囊肿感染: 随机开放标签多中心DIPAK-1研究的中期分析

2016-12-1915
OAAI
Estimation of Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease

常染色体显性多囊肾病肾总体积的估计

2015-11-0135
PREAI
Urine and Plasma Osmolality in Patients with Autosomal Dominant Polycystic Kidney Disease: Reliable Indicators of Vasopressin Activity and Disease Prognosis?

常染色体显性多囊肾病患者的尿和血浆渗透压: 加压素活性和疾病预后的可靠指标?

2015-04-2518
OAAI
Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease
2014-12-0197
OAAI
Rationale and Design of the DIPAK 1 Study: A Randomized Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in Autosomal Dominant Polycystic Kidney Disease

DIPAK 1研究的基本原理和设计: 一项随机对照临床试验,评估兰瑞肽在常染色体显性多囊肾疾病中阻止疾病进展的疗效

2014-03-0161
OAAI